세계의 대사 어세이 시장 예측(-2028년) : 제품별, 기술별, 용도별, 최종사용자별, 지역별
Metabolism Assays Market by Product, Technology, Application (Diagnostics, Research), End User, & Region - Global Forecast to 2028
상품코드:1357250
리서치사:MarketsandMarkets
발행일:2023년 09월
페이지 정보:영문 188 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
대사 어세이 시장 규모는 예측 기간 중 CAGR 7.8%로 확대하며, 2023년 14억 달러에서 2028년에는 21억 달러에 달할 것으로 예측되고 있습니다.
이 시장의 성장은 정부의 신진대사 연구 촉진 및 자금 지원, 피트니스 및 스포츠 산업에서 신진대사 분석 방법의 사용 확대, 조기 진단에 대한 인식 증가가 주요 요인으로 작용하고 있습니다. 그러나 대사 분석의 높은 비용 문제는 시장 성장을 저해하는 요인으로 작용하고 있습니다.
제품별로는 2022년 분석 키트 및 시약 부문이 제품 시장을 주도했습니다. 또한 이 부문은 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예상됩니다. 웨어러블 기기 등 기술과의 통합과 주요 용도인 진단에 광범위하게 사용되면서 큰 점유율을 차지하고 있습니다.
최종사용자별로는 제약 및 생명공학 기업, CRO 및 학술연구 기관 부문이 2022년 대사 분석 시장을 주도할 것으로 예상됩니다. 진단 실험실 부문은 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이 부문의 높은 점유율은 대사 연구에 대한 제약 및 생명공학 기업의 R&D 투자 증가에 기인하는 것으로 보입니다.
지역별로 보면 예측 기간 중 북미가 높은 시장 점유율을 차지할 것으로 예상됩니다. 신약 개발, 독성 시험 및 개발 관련 제약 및 생명공학 산업의 견고한 존재와 대상 질환 인구 증가가 대사 분석 시장의 성장을 지원하고 있습니다. 그러나 아시아태평양은 예측 기간 중 가장 높은 CAGR을 기록할 것으로 예상됩니다.
세계의 대사 어세이 시장에 대해 조사했으며, 제품별, 기술별, 용도별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
서론
시장 역학
가격 분석
특허 분석
밸류체인 분석
공급망 분석
에코시스템 분석
Porter's Five Forces 분석
규제 분석
무역 분석
기술 분석
2023-2024년의 주요 컨퍼런스와 이벤트
비즈니스에 영향을 미치는 동향/혼란
주요 이해관계자와 구입 기준
제6장 대사 어세이 시장, 제품별
서론
어세이 키트와 시약
계측기와 애널라이저
제7장 대사 어세이 시장, 기술별
서론
비색 분석
형광 분석
분광분석
제8장 대사 어세이 시장, 용도별
서론
진단
연구
제9장 대사 어세이 시장, 최종사용자별
서론
병원
진단 연구소
제약·바이오테크놀러지 기업, CRO·학술연구기관
제10장 대사 어세이 시장, 지역별
서론
북미
유럽
아시아태평양
기타 지역
제11장 경쟁 구도
개요
주요 참여 기업 전략/유력 기업
시장 주요 참여 기업의 매출 점유율 분석
시장 순위 분석
기업 평가 쿼드런트(2022년)
스타트업/중소기업용 기업 평가 쿼드런트(2022년)
경쟁 벤치마킹
경쟁 시나리오
제12장 기업 개요
주요 참여 기업
THERMO FISHER SCIENTIFIC INC.
MERCK KGAA
ABCAM PLC.
AGILENT TECHNOLOGIES INC.
KANEKA EUROGENTEC S.A.
SARTORIUS AG
PROMEGA CORPORATION
ELABSCIENCE BIOTECHNOLOGY INC.
RAYBIOTECH LIFE, INC.
BMG LABTECH
BIOTREND CHEMIKALIEN GMBH
기타 기업
3H BIOMEDICAL AB
BIOASSAY SYSTEMS
EMELCA BIOSCIENCE
CREATIVE BIOARRAY
TEMPO BIOSCIENCE, INC.
NCARDIA
NOVOCIB
ETON BIOSCIENCE, INC.
CAYMAN CHEMICAL COMPANY
ENZO LIFE SCIENCES, INC.
ABNOVA CORPORATION
제13장 부록
KSA
영문 목차
영문목차
The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth of this market is majorly driven by the promotion of metabolic research and funding by the government, the growing use of metabolism assays in fitness and sports industry, and an increase in the awareness of early diagnosis. However, issues related high cost of metabolism assays restrain the growth of this market.
Scope of the Report
Years Considered for the Study
2021-2028
Base Year
2022
Forecast Period
2023-2028
Units Considered
USD
Segments
Product,Technology,Application,End User,Region
Regions covered
North America, Europe, APAC, RoW
"The assay kits & reagents segment accounted for the highest market share in the metabolism assays market, by product, during the forecast period."
Based on the product segment, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share is due to their integration with technologies, such as wearable devices and wide use in diagnostics as it is the major application.
"Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes accounted for the highest CAGR during the forecast period."
Based on end users, the metabolism assays market is segmented into hospitals, diagnostic laboratories, and pharmaceutical & biotechnology companies and CROs & academic research institutes. The pharmaceutical & biotechnology companies and CROs & academic research institutes segment dominated the metabolism assays market in 2022. The diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period. The large share of this segment can be attributed to increasing R&D investments by pharmaceutical & biotechnology companies on metabolic research.
"The North America segment accounted for the highest market share in the metabolism assays market, by region, during the forecast period."
Based on the region, the global metabolism assays market is categorized into North America, Europe, Asia Pacific, and Rest of the World. During the forecast period North America is expected to witness a high market share. The presence of robust pharma & biotech industries who are involved in drug discover, toxicity testing & development and the increasing target disease population are supporting the growth of the metabolism assays market. However, Asia Pacific is expected to register highest CAGR during the forecast period.
Breakdown of supply-side primary interviews by company type, designation, and region:
By Company Type: Tier 1 (30%), Tier 2 (48%), and Tier 3 (22%)
By Designation: C-level (28%), Director-level (33%), and Others (39%)
By Region: North America (21%), Asia-Pacific (34%), Europe (30%), and RoW (15%)
Prominent companies include Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), Kaneka Eurogentec S.A. (Belgium), Sartorius AG (Germany), Promega Corporation (US), Elabscience Biotechnology Inc. (US), RayBiotech Life Inc. (US), BMG LABTECH (Germany), BIOTREND ChemiKalien GmbH (Germany), 3H Biomedical AB (Sweden), BioAssay Systems (US), EMELCA Bioscience (Netherlands), Creative Bioarray (US), Tempo Bioscience, Inc (US), Ncardia (Netherlands), NOVOCIB (France), Eton Bioscience Inc. (US), Cayman Chemical Company (US), Enzo Lifesciences, Inc. (US), and Abnova Corporation (Taiwan).
Research Coverage
This research report categorizes the metabolism assays market by product, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the metabolism assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product & service launches, mergers and acquisitions, and recent developments associated with the metabolism assays market. Competitive analysis of upcoming startups in the metabolism assays market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall metabolism assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the metabolism assays market
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the metabolism assays market.
Market Development: Comprehensive information about lucrative markets - the report analyses the metabolism assays market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the metabolism assays market
Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US), among others in the metabolism assays market strategies.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 METABOLISM ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
TABLE 2 KEY DATA FROM PRIMARY SOURCES
FIGURE 2 KEY INDUSTRY INSIGHTS
2.1.2.1 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
TABLE 4 PORTER'S FIVE FORCES ANALYSIS: METABOLISM ASSAYS MARKET
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.1.1 US
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
5.9.1.2 Canada
TABLE 6 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 Japan
TABLE 7 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.9.3.2 China
TABLE 8 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.9.3.3 India
5.10 TRADE ANALYSIS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018-2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018-2022 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
TABLE 11 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2023-2024
5.13 TRENDS/DISRUPTIONS IMPACTING BUSINESSES
5.13.1 REVENUE SHIFT IN METABOLISM ASSAYS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
5.14.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
TABLE 13 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
6 METABOLISM ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 14 METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
6.2 ASSAY KITS & REAGENTS
6.2.1 COST-EFFECTIVENESS TO INCREASE ADOPTION IN DRUG DISCOVERY
TABLE 118 KANEKA EUROGENTEC S.A.: BUSINESS OVERVIEW
FIGURE 37 KANEKA EUROGENTEC S.A.: COMPANY SNAPSHOT (2022)
12.1.6 SARTORIUS AG
TABLE 119 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 38 SARTORIUS AG: COMPANY SNAPSHOT (2022)
TABLE 120 SARTORIUS AG: PRODUCT LAUNCHES
12.1.7 PROMEGA CORPORATION
TABLE 121 PROMEGA CORPORATION: BUSINESS OVERVIEW
12.1.8 ELABSCIENCE BIOTECHNOLOGY INC.
TABLE 122 ELABSCIENCE BIOTECHNOLOGY INC.: BUSINESS OVERVIEW
12.1.9 RAYBIOTECH LIFE, INC.
TABLE 123 RAYBIOTECH LIFE, INC.: BUSINESS OVERVIEW
12.1.10 BMG LABTECH
TABLE 124 BMG LABTECH: BUSINESS OVERVIEW
TABLE 125 BMG LABTECH: PRODUCT LAUNCHES
12.1.11 BIOTREND CHEMIKALIEN GMBH
TABLE 126 BIOTREND CHEMIKALIEN GMBH: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 3H BIOMEDICAL AB
12.2.2 BIOASSAY SYSTEMS
12.2.3 EMELCA BIOSCIENCE
12.2.4 CREATIVE BIOARRAY
12.2.5 TEMPO BIOSCIENCE, INC.
12.2.6 NCARDIA
12.2.7 NOVOCIB
12.2.8 ETON BIOSCIENCE, INC.
12.2.9 CAYMAN CHEMICAL COMPANY
12.2.10 ENZO LIFE SCIENCES, INC.
12.2.11 ABNOVA CORPORATION
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
